Genmab — Maj 2020
-
-
Severance confirms efficacy of amivantamab for mutant lung cancer http://m.koreabiomed.com/news/articleView.html?idxno=8283
-
Halozyme Earns $15M Milestone Payment From Janssen https://www.socaltech.com/halozyme_earns___m_milestone_payment_from_janssen/s-0079866.html
-
-
Transalp - Janssen forventer at indsende en ansøgning til godkendelse sidst på året. Hvilket JNJ sagde i forbindelse med Q2 regnskab.
-
Q1 regnskab
-
God morgen.
-
About Non-Small Cell Lung Cancer (NSCLC)
In the U.S., lung cancer is the second most common cancer in both men and women, after skin cancer; NSCLC makes up 80-85 percent of all lung cancers.[8],[9] The main subtypes of NSCLC are adenoca rcinoma, squamous cell carcinoma, and large cell carcinoma.10 The most common driver mutation for NSCLC is the EGFR genetic alteration, which is a receptor tyrosine kinase that helps cells grow and divide.[10] -
EGFR mutations are present in 10 to 15 percent of patients with NSCLC and occur in 40 to 50 percent of Asian patients who have NSCLC adenocarcinoma.[11],[12],[13] EGFR exon 20 insertion mutations identify a distinct subset of lung adenocarcinomas, accounting for at least nine percent of all EGFR mutations.[14] The five-year survival rate for patients with metastatic NSCLC is currently six percent.[15]
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind